Literature DB >> 22173161

Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice.

Qiang Zhu1, Li Zou, Kumaravelu Jagavelu, Douglas A Simonetto, Robert C Huebert, Zhi-Dong Jiang, Herbert L DuPont, Vijay H Shah.   

Abstract

BACKGROUND & AIMS: Liver fibrosis is associated with angiogenesis and leads to portal hypertension. Certain antibiotics reduce complications of liver failure in humans, however, the effects of antibiotics on the pathologic alterations of the disease are not fully understood. The aim of this study was to test whether the non-absorbable antibiotic rifaximin could attenuate fibrosis progression and portal hypertension in vivo, and explore potential mechanisms in vitro.
METHODS: The effect of rifaximin on portal pressure, fibrosis, and angiogenesis was examined in wild type and Toll-like receptor 4 (TLR4) mutant mice after bile duct ligation (BDL). In vitro studies were carried out to evaluate the effect of the bacterial product and TLR agonist lipopolysaccharide (LPS) on paracrine interactions between hepatic stellate cells (HSC) and liver endothelial cells (LEC) that lead to fibrosis and portal hypertension.
RESULTS: Portal pressure, fibrosis, and angiogenesis were significantly lower in BDL mice receiving rifaximin compared to BDL mice receiving vehicle. Studies in TLR4 mutant mice confirmed that the effect of rifaximin was dependent on LPS/TLR4 pathway. Fibronectin (FN) was increased in the BDL liver and was reduced by rifaximin administration and thus, was explored further in vitro as a potential mediator of paracrine interactions of HSC and LEC. In vitro, LPS promoted FN production from HSC. Furthermore, HSC-derived FN promoted LEC migration and angiogenesis.
CONCLUSIONS: These studies expand our understanding of the relationship of intestinal microbiota with fibrosis development by identifying FN as a TLR4 dependent mediator of the matrix and vascular changes that characterize cirrhosis. Copyright Â
© 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22173161      PMCID: PMC3307873          DOI: 10.1016/j.jhep.2011.11.013

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  41 in total

Review 1.  The intestinal flora and bacterial infection in cirrhosis.

Authors:  Stephen M Riordan; Roger Williams
Journal:  J Hepatol       Date:  2006-09-01       Impact factor: 25.083

2.  Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis.

Authors:  Pablo Bellot; Juan Carlos García-Pagán; Rubén Francés; Juan G Abraldes; Miguel Navasa; Miguel Pérez-Mateo; José Such; Jaime Bosch
Journal:  Hepatology       Date:  2010-10-26       Impact factor: 17.425

3.  Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.

Authors:  Dominique Thabut; Chittaranjan Routray; Gwen Lomberk; Uday Shergill; Kevin Glaser; Robert Huebert; Leena Patel; Tetyana Masyuk; Boris Blechacz; Andrew Vercnocke; Erik Ritman; Richard Ehman; Raul Urrutia; Vijay Shah
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

Review 4.  Alcoholic liver disease and the gut-liver axis.

Authors:  Gyongyi Szabo; Shashi Bala
Journal:  World J Gastroenterol       Date:  2010-03-21       Impact factor: 5.742

5.  Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver.

Authors:  Kumaravelu Jagavelu; Chittaranjan Routray; Uday Shergill; Steven P O'Hara; William Faubion; Vijay H Shah
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

6.  Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells.

Authors:  Yong-Han Paik; Robert F Schwabe; Ramón Bataller; Maria P Russo; Christian Jobin; David A Brenner
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

7.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

8.  Development of an experimental model of induced bacterial peritonitis in cirrhotic rats with or without ascites.

Authors:  Elisabet Sánchez; José Such; Maite Teresa Chiva; Germán Soriano; Teresa Llovet; Javier Mercè; Francisco Sancho; Carlos Muñoz; Xiao-yu Song; Miguel Pérez-Mateo; Joaquín Balanzó; Carlos Guarner
Journal:  Am J Gastroenterol       Date:  2007-06       Impact factor: 10.864

9.  Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis.

Authors:  W R Jarnagin; D C Rockey; V E Koteliansky; S S Wang; D M Bissell
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

10.  Mechanism of Liver Injury during Obstructive Jaundice: Role of Nitric Oxide, Splenic Cytokines, and Intestinal Flora.

Authors:  Ji-Young Hong; Eisuke F Sato; Keiichi Hiramoto; Manabu Nishikawa; Masayasu Inoue
Journal:  J Clin Biochem Nutr       Date:  2007-05       Impact factor: 3.114

View more
  51 in total

Review 1.  Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

Authors:  Aldo J Montano-Loza; Ragesh B Thandassery; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

Review 2.  Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes.

Authors:  Michael Kriss; Elizabeth C Verna; Hugo R Rosen; Catherine A Lozupone
Journal:  Transplantation       Date:  2019-04       Impact factor: 4.939

Review 3.  Hepatic inflammation and fibrosis: functional links and key pathways.

Authors:  Ekihiro Seki; Robert F Schwabe
Journal:  Hepatology       Date:  2015-01-28       Impact factor: 17.425

Review 4.  Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.

Authors:  Dmitry Victorovich Garbuzenko
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 5.  Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.

Authors:  Gyorgy Baffy
Journal:  Dig Dis Sci       Date:  2018-01-22       Impact factor: 3.199

Review 6.  Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.

Authors:  Jaume Bosch; Roberto J Groszmann; Vijay H Shah
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

Review 7.  Recent advancement of molecular mechanisms of liver fibrosis.

Authors:  Ekihiro Seki; David A Brenner
Journal:  J Hepatobiliary Pancreat Sci       Date:  2015-04-13       Impact factor: 7.027

8.  Angiotensin II facilitates fibrogenic effect of TGF-β1 through enhancing the down-regulation of BAMBI caused by LPS: a new pro-fibrotic mechanism of angiotensin II.

Authors:  Yu-Sheng Li; Shu-Yuan Ni; Ying Meng; Xiao-Lan Shi; Xu-Wen Zhao; Hai-Hua Luo; Xu Li
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

Review 9.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 10.  Regulation of wound healing and organ fibrosis by toll-like receptors.

Authors:  Peter Huebener; Robert F Schwabe
Journal:  Biochim Biophys Acta       Date:  2012-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.